[10]Peiffer D, Howard FM, Chen N, et al. Epidemiology and prognosis of HER2-low breast cancer (BC) in the National Cancer Data Base (NCDB). 2022 SABCS. Abstract HER2-11. [11]Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-...
Wang HB. Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study. Front Oncol. 2023 Mar 29;13:1130734. doi: 10.3389/fonc.2023.1130734. PMID: 37064...
[9]Agostinetto, E. et al. HER2-low breast cancer: Molecular characteristics and prognosis. Cancers 13, 2824 (2021). [10]Won, H. S. et al. Clinical significance of HER2-low expression in early breast cancer: A nationwide study from the Korean breast cancer society. Breast Cancer Res. 2...
Traditionally, the HER2-low entity was classified as HER2-negative when evaluating prognosis and administrating treatment in patients with breast cancer brain metastasis (BCBM). Trastuzumab deruxtecan (T-DXd) was proved to have potent efficacy in HER2-low breast cancer, even with brain metastasis,...
[5] Agostinetto E, et al. HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers (Basel). 2021;13(11):2824. [6] Tarantino P, et al. Abstract HER2-05: HER2-05 comprehensive genomic characterization of HER2-low breast cancer....
[15]Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, Sotiriou C, de Azambuja E. HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel) 2021;13:2824. [16]Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra ...
[3] Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, Huo D, Howard FM. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 Apr 1;9(4):500-510. doi: 10.1001/jamaoncol.2022.7476. PMID: ...
15. Peiffer DS, et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol. 2023;9(4):500–10. 16. Miglietta F, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Canc...
[1] HER2-low breast cancer, Molecular characteristics andprognosis,Cancers, 2021;13:2824 [2] Prevalence of HER2 low in breast cancer subtypes using the VENANA anti-HER2/neu (4B5) assay [J]. J Clin Oncol, 2021, 39 (15_Suppl): 1021. [3] Antitumor activity and safetyof trastuzumab der...
4. Agostinetto E, Rediti M, Fimereli D, et al. HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers (Basel). 2021 Jun 5;13(11):2824. 5. Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer[J]. ...